Gapping up
In reaction to earnings/guidance:
- LMT +1.5%, BAC +1.2%, JNJ +0.6%
Other news:
- BLU +98.2% (to be acquired by GSK for $14.75 per share)
- ALVO +5.8% (has been informed by the FDA that the responses provided to the FDA Form 483 on April 3 2023 following the conclusion of the reinspection of the company's Reykjavik facility on March 17 2023 are currently under review)
- NKTX +3.9% (presents preclinincal data)
- ORGN +3% (strategic partnership with SCG Packaging)
- HCM +2.3% (receives NDA acceptance in China for Fruquintinib in second-line gastric cancer)
- BWXT +1.9% (awarded $45 bln DOE contract) SSL +1.4% (secures $3 bln five-year term loan and revolving credit facility agreement)
- JELD +1.1% (selling Australasia business for $461 mln)
- MT +1.1% (establishes renewable energy JV with Casa dos Ventos in Brazil)
Analyst comments:
- RUN +4.1% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- BJRI +3.2% (upgraded to Outperform from Neutral at Wedbush)
- CMCSA +1.3% (upgraded to Overweight from Neutral at Atlantic Equities)
- EMR +1.1% (upgraded to Outperform from Peer Perform at Wolfe Research)